文献速递骨软组织肉瘤与黑色素瘤

BRAF野生型晚期黑色素瘤免疫检查点抑制的成本效益

Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
PubMed 文献 · J Clin Oncol · 2017-02-21

研究采用美国支付方视角的马尔可夫模型, lifetime horizon,评估一线PEM每3周、NIVO、IPI、NIVO+IPI、PEM每2周等方案序贯治疗BRAF野生型晚期黑色素瘤的成本(2016年美元)与QALY。结果显示,PEM每3周序贯二线IPI比达卡巴嗪序贯IPI再NIVO或IPI序贯NIVO更有效且成本更低;与一线达卡巴嗪相比,NIVO序贯IPI的增量成本效果比为90,871美元/QALY,一线NIVO+IPI序贯卡铂+紫杉醇化疗为198,867美元/QALY。

要点

  • PEM每3周序贯二线IPI较达卡巴嗪序贯IPI再NIVO或IPI序贯NIVO更有效且成本更低。
  • 与一线达卡巴嗪相比,NIVO序贯IPI的增量成本效果比为90,871美元/QALY。
  • 一线NIVO+IPI序贯卡铂+紫杉醇化疗的增量成本效果比为198,867美元/QALY。

核心结论

  • 对于未经治疗的BRAF野生型晚期黑色素瘤患者,一线PEM每3周序贯二线IPI或一线NIVO序贯二线IPI是最具成本效益的免疫治疗方案。

研究设计与样本

  • 采用美国支付方视角和终身时间范围的马尔可夫模型,估算成本(2016年美元)和QALY。
  • 评估一线NIVO、IPI、NIVO+IPI、PEM每2周和PEM每3周等治疗序贯策略。
  • 健康状态定义为初始治疗、第一次和第二次进展以及死亡。
  • 状态间转换概率基于随机III期试验的药物停药率、不良事件频率、疾病进展和死亡数据。
  • 进行确定性和概率敏感性分析以评估模型不确定性。

主要发现

  • PEM每3周序贯二线IPI比达卡巴嗪序贯IPI再NIVO或IPI序贯NIVO更有效且成本更低。
  • 与一线达卡巴嗪治疗策略相比,NIVO序贯IPI的增量成本效果比为90,871美元/QALY。
  • 一线NIVO+IPI序贯卡铂+紫杉醇化疗的增量成本效果比为198,867美元/QALY。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Patients who are diagnosed with stage IV metastatic melanoma have an estimated 5-year relative survival rate of only 17%. Randomized controlled trials of recent US Food and Drug Administration-approved immune checkpoint inhibitors-pembrolizumab (PEM), nivolumab (NIVO), and ipilumumab (IPI)-demonstrate improved patient outcomes, but the optimal treatment sequence in patients with BRAF wild-type metastatic melanoma remains unclear. To inform policy makers about the value of these treatments, we developed a Markov model to compare the cost-effectiveness of different strategies for sequencing novel agents for the treatment of advanced melanoma. Materials and Methods We developed Markov models by using a US-payer perspective and lifetime horizon to estimate costs (2016 US$) and quality-adjusted life years (QALYs) for treatment sequences with first-line NIVO, IPI, NIVO + IPI, PEM every 2 weeks, and PEM every 3 weeks. Health states were defined for initial treatment, first and second progression, and death. Rates for drug discontinuation, frequency of adverse events, disease progression, and death obtained from randomized phase III trials were used to determine the likelihood of transition between states. Deterministic and probabilistic sensitivity analyses were conducted to evaluate model uncertainty. Results PEM every 3 weeks followed by second-line IPI was both more effective and less costly than dacarbazine followed by IPI then NIVO, or IPI followed by NIVO. Compared with the first-line dacarbazine treatment strategy, NIVO followed by IPI produced an incremental cost effectiveness ratio of $90,871/QALY, and first-line NIVO + IPI followed by carboplatin plus paclitaxel chemotherapy produced an incremental cost effectiveness ratio of $198,867/QALY. Conclusion For patients with treatment-naive BRAF wild-type advanced melanoma, first-line PEM every 3 weeks followed by second-line IPI or first-line NIVO followed by second-line IPI are the most cost-effective, immune-based treatment strategies for metastatic melanoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kohn CG, Zeichner SB, Chen Q, et al. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. J Clin Oncol. 2017. PMID: 28221865. doi:10.1200/JCO.2016.69.6336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。